Abstract. Inguinal lymph node mass as the first sign in patients with ovarian cancer represents a rare situation, with only few cases being reported so far. We present the case of a 46-year-old patient who presented for the apparition of bilateral inguinal tumoral masses in the absence of any other pathological signs. The biopsy revealed the presence of an adenocarcinoma with probable genital origin; however, neither the gynaecological examination nor the computed tomography demonstrated the presence of any suspect lesion. The patient was submitted to a positron emission computed tomography which revealed a high capitation in both adnexal areas as well as at the level of the inguinal lymph nodes. The patient was submitted to surgery, the frozen section of the adnexas confirming the ovarian origin of the tumor. Complete cytoreduction to no residual disease was successfully performed. At one-year follow-up the patient is free of any recurrent disease.

Ovarian cancer remains an aggressive gynaecological malignancy associated with poor survival rates especially if complete cytoreductive surgery cannot be achieved. Most commonly it metastasises via peritoneal, haematogenous or lymphatic route, leading to the apparition of disseminated lesion from the moment of the initial diagnosis. However, even in cases presenting systemic disease, it seems that performing a maximal cytoreductive surgical procedure remains the only therapeutic chance to improve the overall survival (1-8). Most commonly patients diagnosed with ovarian cancer complain of weight loss, abdominal discomfort or distension, constipation or early satiety. In a very small number of cases all these signs might be missing, the only complain of the patient being related to the apparition of a unilateral or bilateral inguinal mass. This represents less than 3% of cases and consists of cases in which the lymphatic spread is directed mainly to the groin lymph node stations (9).

Case Report

A 46-year-old patient with no significant medical history presented for the apparition of bilateral inguinal tumoral masses; the patient denied other signs or symptoms such as weight loss, fever, abdominal pain or constipation. A biopsy of the inguinal masses was performed, the histopathological studies revealing the presence of tumoral cells mimicking an adenocarcinoma probably originating from the gynaecological tract. The patient was submitted to vaginal ultrasound, cervical and endometrial biopsies; however no pathological results were found. She was also submitted to a full body computed tomography which revealed the presence of a few pelvic adenopathies, without any other modifications, so she was also submitted to a PET CT which revealed the presence of a high fixation area at the level of the both adnexal areas as well as in the inguinal areas; however, it should be mentioned that although both adnexas presented an increased fixation at PET CT none of the two ovaries were modified in volume at the standard computed tomography (Figure 1). The laboratory analyses revealed an
increased level of CA 125 (of 67 UI/ml) without any other modifications. We submitted the patient to surgery, a bilateral adnexectomy being performed. The frozen section confirmed the origin of the tumoral process at the level of the both ovaries, so the patient was submitted to debulking surgery consisting of total hysterectomy, bilateral adnexectomy, omentectomy, peritoneal biopsies, pelvic and para-aortic lymph node dissection, as well as bilateral inguinal lymph node dissection (Figures 2-6). The histopathological studies revealed the presence of lymph node metastases in one pelvic lymph node while all the 18 lymph nodes removed from the inguinal areas presented tumoral deposits. At one-month follow-up, the CA 125 levels dropped at 28 UI/ml. However, the patient was submitted to six cycles of taxanes and platinum based chemotherapy. At one-year follow-up the patient is free of any recurrent disease.

Discussion

Ovarian cancer has a high propensity of developing lymph node metastases, the most commonly involved groups being located in the pelvic and para-aortic region, the estimated incidence of such lesions ranging between 14% and 70% (10). Anatomical studies demonstrated that ovarian lymphatic
drainage usually occurs via the infundibulo-pelvic ligament to
the para-aortic lymph nodes, and only after blocking these
stations occur a retrograde drainage to the inguinal lymph
nodes develop (1, 2, 11). However, in our case both the
preoperative PET CT and the histological findings
demonstrated the presence of a single pelvic lymph node
metastasis, this finding couldn’t support the theory of lymphatic
drainage blocking followed by the retrograde dissemination.

When it comes to the issue of inguinal lymph node
metastases with ovarian cancer origin, the reported incidence
is less than 3% (9). Therefore, inguinal lymph node
dissection is not routinely recommended in ovarian cancer
patients even if an advanced stage of the disease is expected.

The main mechanisms of spread of the ovarian tumoral
cells in the inguinal lymph nodes involve tumoral
dissemination through the round ligaments (12).

As for the preoperative workup which might establish the
involvement of the inguinal lymph nodes, it seems that
positron emission computed tomography (PET CT) plays a
central role. In a similar case which was reported by Manci
et al., a 58-year-old patient who had been initially diagnosed
with bilateral groin lymph node metastases, all the performed
investigations (including colonoscopy, upper digestive
endoscopy, transvaginal ultrasound, endometrial and cervical
biopsies and full body computed tomography) failed to
demonstrate the origin of these malignant elements; however,
the only preoperative investigation which orientated the
initial diagnosis was a PET CT study which demonstrated
the presence of a high metabolic uptake in the both adnexal
and inguinal areas. The patient was submitted to bilateral
adnexectomy, the frozen sections confirming the presence of
a serous papilliferous bilateral ovarian adenocarcinoma and
therefore the intervention was completed by performing a
total hysterectomy, omentectomy, pelvic and para-aortic
lymph node dissection as well as bilateral inguinal lymph
node dissection. Surprisingly, only the inguinal lymph nodes
presented tumoral involvement, all the other retrieved lymph

Figure 2. Intraoperative aspect – removal of an inguinal tumoral mass.

Figure 3. The final aspect after inguinal lymph node dissection.

Figure 4. The final aspect of pelvic lymph node dissection.
nodes (from the pelvic and para-aortic areas) presenting no signs of disease. These data come to demonstrate that in certain cases ovarian cancer can metastasize directly in the inguinal lymph nodes even in the absence of other distant lesions (13).

Another similar finding comes from the Indian authors, who reported the case of a 35-year-old patient who presented for the apparition of an ulcerated tumoral mass in the left inguinal region in the absence of any other modification. However, due to the presence of high levels of CA 125 (of 412 IU/ml) the patient was treated as an ovarian cancer, three cycles of paclitaxel and carboplatin being administrated. This regimen induced a complete regression of the groin mass; however, the patient was submitted to total hysterectomy, bilateral adnexectomy, omentectomy and groin lymph node dissection, the histopathological studies confirming the presence of tumoral cells at the level of the left ovary and left inguinal nodes (14).

In a study conducted in Istanbul, Turkey, Ulker et al. investigated the lymphatic pattern of spread on 62 consecutive patients submitted to surgery for epithelial ovarian cancer between January 2003 and February 2013. According to the authors of the study, staging procedures included peritoneal washing, multiple peritoneal biopsies, total hysterectomy with bilateral adnexectomy, appendectomy, omentectomy as well as pelvic and para-aortic lymph node dissection; in this study pelvic lymph node dissection included the common, external, internal groups but also the lymph nodes at the level of the inguinal ligament, while para-aortic lymph node dissection included the ganglia groups at the level of the great vessels, up to the level of the renal vessels on the both sides. The authors failed to demonstrate the presence of any correlation between the laterality of the ovarian tumor and the involved pelvic and inguinal lymph nodes. However, a significant correlation was established between the positivity of the peritoneal fluid cytology and the presence of lymph node metastases. Moreover, a higher FIGO stage was significantly associated with the risk of lymph node metastases (11).

In a more recent study which was conducted this time in India, the authors reviewed data originating from 324 patients and reported seven cases of ovarian cancer patients presenting inguinal lymph node metastases. In four of the seven cases the presence of groin swelling represented the only symptom at the time of presentation. When it comes to the extent of the disease, only three of the 324 cases presented no adnexal masses and no other distant tumoral masses. Due to the extent of the disease, only two patients were submitted to per-primam cytoreductive surgery while in all other cases neoadjuvant chemotherapy was needed in order to increase the resectability rate. However, the histopathological studies of the two patients submitted to surgery as the first intention therapeutic procedure demonstrated the presence of disseminated metastatic lesions at the level of the peritoneal biopsies as well as at the level of the pelvic, inguinal and para-aortic removed lymph nodes,
demonstrating in this way that the contamination of the inguinal lymph nodes usually occur as part of the systemic development of this malignancy (15).

Another interesting aspect of the case that we present is the fact that both ovaries were normal sized and presented no macroscopic signs of tumoral development, only the PET-CT demonstrating the presence of bilateral fixation. This phenomenon is called “normal size ovary carcinoma syndrome” and has been reported in only 1% of all patients diagnosed with ovarian cancer (16-18).

Conclusion

The presence of isolated lymph node metastases in patients with ovarian cancer is a rare event, only few cases being reported so far. Most often tumoral invasion at this level occurs via the round ligament in a retrograde route which is induced by the tumoral occlusion of the pelvic and para-aortic lymph nodes. Moreover, the development of isolated inguinal lymph node metastases in a patient with normal size ovaries is even scarcer. However, ovarian cancer should not be omitted from the list of the differential diagnosis in patients with isolated inguinal tumoral masses especially if these are associated with higher preoperative levels of CA 125.

References

1 Bacalbasa N, Balescu I, Dima S and Popescu I: Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases. Anticancer Res 35: 6919-6923, 2015.
2 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248-1259, 2002.
3 Bacalbasa N, Balescu I, Dima S, Brasoveanu V and Popescu I: Splenectomy as part of cytoreductive surgery in recurrent epithelial ovarian cancer. Anticancer Res 35: 5097-5101, 2015.
4 Bacalbasa N, Balescu I, Dima S, Brasoveanu V and Popescu I: Pancreatic resection as part of cytoreductive surgery in advanced-stage and recurrent epithelial ovarian cancer – A single-center experience. Anticancer Res 35: 4125-4129, 2015.
5 Bacalbasa N, Dima S, Balescu I, David L, Brasoveanu V and Popescu I: Results of primary cytoreductive surgery in advanced-stage epithelial ovarian cancer: A single-center experience. Anticancer Res 35: 4099-4104, 2015.
6 Bacalbasa N, Balescu I, Dima S, Herlea V, David L, Brasoveanu V and Popescu I: Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management. Anticancer Res 35: 2315-2320, 2015.
7 Bacalbasa N, Dima S, Brasoveanu V, David L, Balescu I, Purnichescu-Purtan R and Popescu I: Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Oncol 13: 235, 2015.
8 Bacalbasa N, Balescu I, Dima S, Brasoveanu V and Popescu I: Hematogenous splenic metastases as an independent negative prognosis factor at the moment of primary cytoreduction in advanced stage epithelial ovarian cancer – a single center experience. Anticancer Res 35: 5649-5654, 2015.
9 Rose PG, Piver MS, Tsukada Y and Lau TS: Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 64: 1508-1513, 1989.
10 Panici PB and Angioli R: Role of lymphadenectomy in ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16: 529-551, 2002.
11 Ulker V, Kuru O, Numanoglu C, Akbayir O, Polat I and Uhtri M: Lymph node metastasis in patients with epithelial ovarian cancer macroscopically confined to the ovary: review of a single-institution experience. Arch Gynecol Obstet 289: 1087-1092, 2014.
12 Metwally IH, Zuhdy M, Hassan A, Alghandour R and Megahed N: Ovarian cancer with metastatic inguinal lymphadenopathy: A case series and literature review. J Egypt Natl Canc Inst 29: 109-114, 2017.
13 Manci N, Bellati F, Graziano M, Pernice M, Muzii L, Angioli R and Benedetti PP: Ovarian cancer, diagnosed with PET, with bilateral inguinal lymphadenopathy as primary presenting sign. Gynecol Oncol 100: 621-622, 2006.
14 Deka P, Shrivastava S, Barmon D, Kataki AC and Sarma A: Ovarian carcinoma in normal size ovaries with inguinal lymph node metastasis: a case report. Cancer Ther Res 2: 3, 2013.
15 Giri S, Shah SH, Batra K, Anu B, Jain V, Shukla H, Sekhon R and Rawal S: Presentation and management of inguinal lymphadenopathy in ovarian cancer. Indian J Surg Oncol 7: 436-440, 2016.
16 Scholz HS, Lax S, TamussinoKF and Petru E: Inguinal lymph node metastasis as the only manifestation of lymphatic spread in ovarian cancer: A case report. Gynecol Oncol 75: 517-518, 1999.
17 Feuer GA, Shevchuk M and Calanog A: Normal-sized ovary carcinoma syndrome. Obstet Gynecol 73: 786-792, 1989.
18 Berek JS and Hacker NF: Practical Gynecologic Oncology. Lippincott Williams and Wilkins (3rd ed.), Philadelphia, pp. 466-467, 1994.

Received November 27, 2017
Revised December 13, 2017
Accepted December 14, 2017